All articles tagged with #biotech acquisition
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, marking the largest deal in Vertex’s history and expanding its commercial endocrinology portfolio with Crinetics’ programs in obesity, diabetes and related endocrine diseases.
Novo Nordisk has made an unsolicited bid to acquire obesity-focused biotech Metsera, aiming to outbid Pfizer, which had previously announced its plan to purchase the firm. The move has sparked a bidding war in the competitive obesity market, with Metsera indicating it considers Novo's offer superior and giving Pfizer a deadline to renegotiate.
Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion to expand into in vivo CAR-T cell therapies, focusing on autoimmune diseases and leveraging Orbital's RNA-based approach to produce CAR-T cells within the body, marking a significant move in the biotech and cell therapy markets.
Eli Lilly is in advanced negotiations to acquire Verve Therapeutics for up to $1.3 billion, aiming to expand its pipeline with gene-editing therapies, particularly targeting cholesterol treatment, in a strategic move during a period of cautious dealmaking in the pharma industry.
Eli Lilly is expanding its presence in the non-opioid pain treatment market by acquiring California biotech SiteOne Therapeutics for up to $1 billion.